Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.
about
Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilizationCD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritisCD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasThe Promise of Preventive Cancer VaccinesTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsThe role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosisImmunotherapy in the treatment of non-small cell lung cancerTreg functional stability and its responsiveness to the microenvironmentScience gone translational: the OX40 agonist storyOX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularizationInvolvement of HAb18G/CD147 in T cell activation and immunological synapse formation.The adaptor TRAF5 limits the differentiation of inflammatory CD4(+) T cells by antagonizing signaling via the receptor for IL-6.Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension.Costimulatory pathways in transplantation.Activation of OX40 augments Th17 cytokine expression and antigen-specific uveitis.OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.OX40L blockade and allergen-induced airway responses in subjects with mild asthmaCD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individualsHDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interactionSimvastatin reduces OX40 and OX40 ligand expression in human peripheral blood mononuclear cells and in patients with atherosclerotic cerebral infarction.OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.Classification of current anticancer immunotherapiesCell surface signaling molecules in the control of immune responses: a tide model.Role of co-stimulation in LeishmaniasisActive vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1.New insights on OX40 in the control of T cell immunity and immune tolerance in vivoK562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals.Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domainRegulation of the PKCθ-NF-κB Axis in T Lymphocytes by the Tumor Necrosis Factor Receptor Family Member OX40OX40 costimulation turns off Foxp3+ Tregs.OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice.Immunotherapy for pancreatic cancer - science driving clinical progress.Genetic and genomic insights into the molecular basis of atherosclerosis.In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammationCutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is rightCD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.Towards a therapeutic breast cancer vaccine: the next steps.
P2860
Q24318411-8549969F-2DA5-4929-9A7A-BB4E8D324469Q24816831-C15AC865-0677-48A4-A520-CBDD161368F2Q26740520-7F32AAB3-D445-40A4-8BDF-9B2A9919B45CQ26783742-BBC78C9B-4DFA-4555-8A10-CB898DE8FAC9Q26996518-88D2A4E0-D7F5-4A04-B3D2-F580CE9BDCF6Q26996707-28ECA6BE-F7F2-494B-B91D-34D0A534CB4BQ27000382-E334653E-954F-4F0D-A452-DB2AC2C4426AQ27008946-B79AF21F-AA6A-4604-ACAD-D5916EB4D059Q27022436-2C55BB74-0EA5-4DC2-8322-3AE4D8650FCEQ28506359-C1EC1B91-128B-4271-BCB8-D9C7255A5236Q33524885-A2B14FB6-B9E2-4ED0-82CB-6FA2B0D7AE71Q33940420-B2D5269F-1577-43A7-B512-2A7C34E5A13FQ34101823-FC41C23F-A1FB-4E9A-AF2C-31557189F6A2Q34187594-079B4B31-C5F5-465F-8919-B54DD70EBEA9Q34358363-361A52A7-EA24-4890-9150-E001F1EEE1AEQ34477650-58996EAA-BFA3-45B8-9839-86651B53419DQ34620982-4E837A2C-F5C5-47BA-859C-AE8D1B66D3AFQ34692141-6C0E613B-D2B2-402E-ABD5-4249BF01719AQ34707183-3A2559A2-141B-42C6-8D5F-CB4406988AB3Q34954124-F6D4ABAB-774D-4E4A-8A9E-3D9AC9900726Q34991508-863A1745-F6AF-48DC-AD25-A384DB53AC69Q35118177-FEF60C8F-B678-4BF3-AF74-60A7CC44F179Q35149637-4198A7D9-D5C7-44C8-9CDA-265CF743A0FBQ35223235-9660A243-22B1-4E5C-B288-1B4B77A05D88Q35566850-35350E2A-05D3-4337-866D-FB083CE82470Q35651705-4826699F-D89D-4005-B7CF-84A7B6FD5AFDQ35676793-740A0A0B-4CBC-4383-94A7-20402D8BABA5Q35685810-CC39CA43-788A-476D-85AF-53F504AFFE22Q35812085-D838BEA8-018E-478C-B77E-1494C7E138DFQ35854792-7510AC48-39EE-47EF-B9C5-D80183256D5DQ35946627-A19C3206-64D2-412D-BCC2-F05E5B10862CQ35990308-D9EA4E09-14DF-4727-A2CE-45619F2C0726Q36007580-2E4BD78B-2F07-4F35-A1EF-8C33AC851F98Q36099421-92A67006-B976-4CDF-9EA8-8D3E5884D22EQ36133140-DCB82682-0733-457C-8FFF-A4724548E578Q36155114-F84EAEED-32E0-41F8-A62A-B2E34FBB8374Q36173559-A56DC7DB-B74C-47C1-ADD1-AB26918DF3B7Q36224132-352C90EE-BFAD-4C5C-ADBF-D52742975F14Q36288270-A718F273-8CDA-43F7-A9E5-83BFCCE4BE88Q36350565-059B4089-4CD9-439A-BF55-885DFD3DF3AA
P2860
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.
@ast
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.
@en
type
label
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.
@ast
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.
@en
prefLabel
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.
@ast
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.
@en
P2093
P2860
P356
P1476
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.
@en
P2093
Andrew D Weinberg
Kazuo Sugamura
Naoto Ishii
P2860
P304
P356
10.1038/NRI1371
P577
2004-06-01T00:00:00Z